Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 34

Results For "REACH"

1153 News Found

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion
News | April 24, 2025

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience


Zydus Medtech inks pact with Braile Biomedica  to commercialise TAVI technology
News | April 18, 2025

Zydus Medtech inks pact with Braile Biomedica to commercialise TAVI technology

Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets


Morepen to add 1,000 medical representatives
News | April 12, 2025

Morepen to add 1,000 medical representatives

The company is targeting a Rs. 1,000 crore finished dosages business within the next five years


Granules India completes acquisition of Senn Chemicals
News | April 11, 2025

Granules India completes acquisition of Senn Chemicals

Strengthening capabilities in Peptide Therapeutics and CDMO services


Alife expands personal care portfolio with Gondhoraj & Neem soap in West Bengal
News | April 07, 2025

Alife expands personal care portfolio with Gondhoraj & Neem soap in West Bengal

The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience


Lupin acquires UK-based Renascience Pharma for £12.3 million
News | April 04, 2025

Lupin acquires UK-based Renascience Pharma for £12.3 million

The portfolio includes branded injectable cephalosporines for infectious diseases


Merck seeks FDA approval for subcutaneous pembrolizumab
Drug Approval | March 29, 2025

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy


Curium completes acquisition of Monrol
News | March 29, 2025

Curium completes acquisition of Monrol

Positions Curium as leading manufacturer of Lu-177 isotope